DE3854213T2 - Analoge der Untereinheit des von rekombinanter DNS abgeleiteten Bordetella-Toxins. - Google Patents

Analoge der Untereinheit des von rekombinanter DNS abgeleiteten Bordetella-Toxins.

Info

Publication number
DE3854213T2
DE3854213T2 DE3854213T DE3854213T DE3854213T2 DE 3854213 T2 DE3854213 T2 DE 3854213T2 DE 3854213 T DE3854213 T DE 3854213T DE 3854213 T DE3854213 T DE 3854213T DE 3854213 T2 DE3854213 T2 DE 3854213T2
Authority
DE
Germany
Prior art keywords
recombinant dna
subunit
analogs
toxin derived
subunits
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3854213T
Other languages
English (en)
Other versions
DE3854213D1 (de
DE3854213T3 (de
Inventor
Iii Walter Neal Burnette
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26788722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE3854213(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of DE3854213D1 publication Critical patent/DE3854213D1/de
Publication of DE3854213T2 publication Critical patent/DE3854213T2/de
Application granted granted Critical
Publication of DE3854213T3 publication Critical patent/DE3854213T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K2039/10—Brucella; Bordetella, e.g. Bordetella pertussis; Not used, see subgroups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DE3854213T 1987-09-04 1988-09-01 Analoge der Untereinheit des von rekombinanter DNS abgeleiteten Bordetella-Toxins. Expired - Lifetime DE3854213T3 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9430787A 1987-09-04 1987-09-04
US23248288A 1988-08-17 1988-08-17

Publications (3)

Publication Number Publication Date
DE3854213D1 DE3854213D1 (de) 1995-08-31
DE3854213T2 true DE3854213T2 (de) 1995-12-07
DE3854213T3 DE3854213T3 (de) 2004-10-21

Family

ID=26788722

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3854213T Expired - Lifetime DE3854213T3 (de) 1987-09-04 1988-09-01 Analoge der Untereinheit des von rekombinanter DNS abgeleiteten Bordetella-Toxins.

Country Status (16)

Country Link
US (1) US5773600A (de)
EP (2) EP0306318B2 (de)
JP (1) JP2918895B2 (de)
KR (1) KR0168039B1 (de)
CN (1) CN1033866C (de)
AT (1) ATE125568T1 (de)
CA (1) CA1341560C (de)
DE (1) DE3854213T3 (de)
DK (1) DK175821B1 (de)
ES (1) ES2076160T5 (de)
FI (1) FI101632B1 (de)
GR (1) GR3017497T3 (de)
IE (1) IE69753B1 (de)
IL (3) IL87608A0 (de)
NO (2) NO301844B1 (de)
WO (1) WO1989001976A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925546A (en) * 1987-11-02 1999-07-20 Chiron S.P.A. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
US6713072B1 (en) * 1987-11-02 2004-03-30 Chiron S.R.L. Immunologically active polypeptides with altered toxicity useful for the preparation of an antipertussis vaccine
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
US5332583A (en) * 1987-11-24 1994-07-26 Connaught Laboratories Limited Vaccine containing genetically-detoxified pertussis holotoxin
US5358868A (en) * 1987-11-24 1994-10-25 Connaught Laboratories Limited Genetic detoxification of pertussis toxin
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
CA2009991A1 (en) * 1989-02-15 1990-08-15 Witold Cieplak Pertussis toxin gene: cloning and expression of protective antigen
US7232671B2 (en) * 1989-02-15 2007-06-19 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Pertussis toxin gene: cloning and expression of protective antigen
EP0396964B1 (de) * 1989-04-28 1995-09-06 SCLAVO S.p.A. Pertussistoxin-Mutanten, dieselbe produzierende Bordetella-Stämme und ihre Verwendung als Vakzin gegen Pertussis
US5786189A (en) * 1989-11-29 1998-07-28 Smithkline Beecham Biologicals (S.A.) Vaccine
GB9326174D0 (en) * 1993-12-22 1994-02-23 Biocine Sclavo Mucosal adjuvant
US20030072774A1 (en) * 1994-06-10 2003-04-17 Diane M. Gajewczyk Proteinaceous adjuvants
EP1234580A1 (de) * 1995-05-04 2002-08-28 Aventis Pasteur Limited Azelluläre Pertussis-Impfstoffe und Verfahren zu deren Herstellung
WO1997043407A1 (en) * 1996-05-10 1997-11-20 Phylomed Corporation Methods for oxidizing disulfide bonds using ozone
FR2754543B1 (fr) * 1996-10-11 1998-12-31 Pasteur Institut Souche de bordetella deficiente dans la production de toxine et exprimant une proteine hydride, liposomes comprenant de la fha et leurs utilisations comme vaccins, et utilisation de la fha pour stimuler les reponses immunitaires
US6818222B1 (en) 1997-03-21 2004-11-16 Chiron Corporation Detoxified mutants of bacterial ADP-ribosylating toxins as parenteral adjuvants
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
GB0313916D0 (en) 2003-06-16 2003-07-23 Glaxosmithkline Biolog Sa Vaccine composition
CA2574953A1 (en) 2004-07-26 2006-02-09 Dow Global Technolgies Inc. Process for improved protein expression by strain engineering
CA2590906C (en) * 2004-12-17 2017-01-03 Nvi Nederlands Vaccininstituut Deacylation of lps in gram negative bacteria
US9580719B2 (en) 2007-04-27 2017-02-28 Pfenex, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
WO2008134461A2 (en) 2007-04-27 2008-11-06 Dow Global Technologies, Inc. Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins
ITMI20090946A1 (it) 2009-05-28 2010-11-29 Novartis Ag Espressione di proteine ricombinanti
MX343356B (es) 2010-03-30 2016-11-03 Pfenex Inc * Toxinas proteicas recombinantes de alto nivel de expresion.
US9169304B2 (en) 2012-05-01 2015-10-27 Pfenex Inc. Process for purifying recombinant Plasmodium falciparum circumsporozoite protein
US20140037680A1 (en) 2012-08-06 2014-02-06 Glaxosmithkline Biologicals, S.A. Novel method
AU2013301312A1 (en) 2012-08-06 2015-03-19 Glaxosmithkline Biologicals S.A. Method for eliciting in infants an immune response against RSV and B. pertussis
MX362793B (es) 2013-03-08 2019-02-13 Janssen Vaccines & Prevention Bv Vacuna acelular contra pertussis.
BE1022008B1 (fr) 2013-08-05 2016-02-03 Glaxosmithkline Biologicals S.A. Compositions immunogenes combinees
CN109172818B (zh) * 2018-08-02 2021-10-22 浙江康佰裕生物科技有限公司 一种蛋白牛痘疫苗及其效力检测方法
US20220047690A1 (en) * 2018-10-15 2022-02-17 Arizona Board Of Regents On Behalf Of The University Of Arizona Vaccine polypeptide compositions and methods

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4704362A (en) * 1977-11-08 1987-11-03 Genentech, Inc. Recombinant cloning vehicle microbial polypeptide expression
FR2590483B1 (fr) * 1985-11-22 1988-12-09 Pasteur Institut Antigenes purifies ayant des proprietes vaccinantes contre b. pertussis, moyens notamment adns recombinants pour les produire et compositions de vaccins les contenant
CA1340373C (en) * 1986-01-28 1999-02-02 Rino Rappuoli Cloning and sequencing of the dna fragment which codes for the five subunits of the pertussis toxin, a hybrid plasmid containing the dna fragment and micro-organisms transformed by the hybrid plasmid and capable of expressing all or some of the subunits of the pertussis toxin
EP0275689B1 (de) * 1986-12-23 1992-09-02 The Board Of Trustees Of The Leland Stanford Junior University Modifiziertes Pertussistoxin
IT1223334B (it) * 1987-11-02 1990-09-19 Sclavo Spa Polipeptidi immunologicamente attivi con una tossicita' alterata utili per la preparazione di un vaccino antipertosse
GB8727489D0 (en) * 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
IT1223529B (it) * 1987-12-18 1990-09-19 Sclavo Spa Epitopo immunodominante protettivo contenuto nella subunita' s1 della tossina della pertosse

Also Published As

Publication number Publication date
FI101632B (fi) 1998-07-31
KR890701758A (ko) 1989-12-21
IE69753B1 (en) 1996-10-02
EP0306318B2 (de) 2004-04-28
CN1033866C (zh) 1997-01-22
JP2918895B2 (ja) 1999-07-12
AU623867B2 (en) 1992-05-28
NO301844B1 (no) 1997-12-15
JPH04501051A (ja) 1992-02-27
NO972642L (no) 1997-07-28
IL87608A0 (en) 1989-01-31
FI101632B1 (fi) 1998-07-31
NO972642D0 (no) 1997-06-09
NO325016B1 (no) 2008-01-14
NO891842L (no) 1989-06-21
IL103121A (en) 1995-08-31
CN1033072A (zh) 1989-05-24
IL103121A0 (en) 1993-02-21
EP0306318B1 (de) 1995-07-26
NO891842D0 (no) 1989-05-03
EP0629696A1 (de) 1994-12-21
KR0168039B1 (ko) 1999-01-15
DE3854213D1 (de) 1995-08-31
FI892131A (fi) 1989-05-03
CA1341560C (en) 2007-10-30
ATE125568T1 (de) 1995-08-15
DE3854213T3 (de) 2004-10-21
FI892131A0 (fi) 1989-05-03
DK216289D0 (da) 1989-05-03
WO1989001976A1 (en) 1989-03-09
US5773600A (en) 1998-06-30
EP0306318A1 (de) 1989-03-08
AU2386488A (en) 1989-03-31
DK175821B1 (da) 2005-03-14
GR3017497T3 (en) 1995-12-31
ES2076160T3 (es) 1995-11-01
ES2076160T5 (es) 2004-12-01
IE882668L (en) 1989-03-04
DK216289A (da) 1989-06-30

Similar Documents

Publication Publication Date Title
DE3854213D1 (de) Analoge der Untereinheit des von rekombinanter DNS abgeleiteten Bordetella-Toxins.
MX9203458A (es) Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
ES2156110T3 (es) Analogos de sub-unidades de toxina del colera derivados de adn recombinante.
ATE181572T1 (de) Ospa proteine von borrelia burgdorferi untergruppen, dafür kodierende gene sowie impfstoffe
KR970009347B1 (en) Chimeric glycoproteins containing immunogenic segments of human parainfluenza virus type 3
NL300183I1 (nl) Acellulair vaccin.
DE3582272D1 (de) Antigenische zubereitungen und isolierung von solchen zubereitungen.
DK0892054T3 (da) Clostridium perfringens-vaccine
DK0563254T3 (da) Anvendelse af IL-4 til forstærkning af immunrespons på immunogener i vacciner
ATE85811T1 (de) Klonierung und sequenzierung des gens, das fuer eine neue pilinische untereinheit von bordetella pertussis kodiert.
ATE159758T1 (de) Azelluläre impfstoffe
DK230890A (da) Dna-fragment, der koder for et pasteurella multocida-toxin eller for en subsekvens eller analog deraf, ekspressionsvektor, der omfatter dna-fragmentet, mikroorganisme, der udtrykker dette, fremgangsmaade til fremstilling af et pasteurella-multocida-toxin, diagnostisk middel samt anvendelse heraf, vaccine indeholdende et pasteurella-multocida-toxinderivat, anvendelse af pasteurella multocida-t m.m.

Legal Events

Date Code Title Description
8363 Opposition against the patent
8366 Restricted maintained after opposition proceedings